Trial Profile

Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

23 Aug 2023 Randomization has been amended in this trial.
01 Jul 2020 Results (n=104) from group A enrolled first 50patients (SOF & OBV/PTV/r and RBV for 12 weeks) and group B enrolled next 54 patients (SOF, SMV, DCV and RBV for 12 weeks) assessing efficacy and safety outcomes published in the Archives of Virology
07 Mar 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com